Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

Paul S. Ritch MD

Professor

Institution: Medical College of Wisconsin
Department: Medicine
Division: Hematology and Oncology - Medicine
Program: Hematology

Member of the Cancer Center


Publications

  • Venous thromboembolism prophylaxis during neoadjuvant therapy for resectable and borderline resectable pancreatic cancer-Is it indicated? (Krepline AN, Christians KK, George B, Ritch PS, Erickson BA, Tolat P, Evans DB, Tsai S) J Surg Oncol 2016 Oct;114(5):581-586 PMID: 27760280 10/22/2016
  • Neoadjuvant therapy for localized pancreatic cancer: guiding principles. (Fathi A, Christians KK, George B, Ritch PS, Erickson BA, Tolat P, Johnston FM, Evans DB, Tsai S) J Gastrointest Oncol 2015 Aug;6(4):418-29 PMID: 26261728 PMCID: PMC4502155 08/12/2015
  • Pre-treatment carbohydrate antigen 19-9 does not predict the response to neoadjuvant therapy in patients with localized pancreatic cancer. (Aldakkak M, Christians KK, Krepline AN, George B, Ritch PS, Erickson BA, Johnston FM, Evans DB, Tsai S) HPB (Oxford) 2015 Oct;17(10):942-52 PMID: 26255895 PMCID: PMC4571763 08/11/2015
  • Use of neoadjuvant therapy in patients 75 years of age and older with pancreatic cancer. (Miura JT, Krepline AN, George B, Ritch PS, Erickson BA, Johnston FM, Oshima K, Christians KK, Evans DB, Tsai S) Surgery 2015 Dec;158(6):1545-55 PMID: 26243342 08/06/2015
  • Neoadjuvant therapy for localized pancreatic cancer: support is growing? (Evans DB, Ritch PS, Erickson BA) Ann Surg 2015 Jan;261(1):18-20 PMID: 25599323 01/20/2015
  • Neoadjuvant chemoradiation with IMRT in resectable and borderline resectable pancreatic cancer. (Kharofa J, Tsai S, Kelly T, Wood C, George B, Ritch P, Wiebe L, Christians K, Evans DB, Erickson B) Radiother Oncol 2014 Oct;113(1):41-6 PMID: 25443499 PMCID: PMC4530020 12/03/2014
  • Diagnostic laparoscopy should be performed before definitive resection for pancreatic cancer: a financial argument. (Jayakrishnan TT, Nadeem H, Groeschl RT, George B, Thomas JP, Ritch PS, Christians KK, Tsai S, Evans DB, Pappas SG, Gamblin TC, Turaga KK) HPB (Oxford) 2015 Feb;17(2):131-9 PMID: 25123702 PMCID: PMC4299387 08/16/2014
  • Phase II trial of vatalanib in patients with advanced or metastatic pancreatic adenocarcinoma after first-line gemcitabine therapy (PCRT O4-001). (Dragovich T, Laheru D, Dayyani F, Bolejack V, Smith L, Seng J, Burris H, Rosen P, Hidalgo M, Ritch P, Baker AF, Raghunand N, Crowley J, Von Hoff DD) Cancer Chemother Pharmacol 2014 Aug;74(2):379-87 PMID: 24939212 PMCID: PMC4461053 06/19/2014
  • Neoadjuvant FOLFIRINOX for borderline resectable pancreas cancer: a new treatment paradigm? (Christians KK, Tsai S, Mahmoud A, Ritch P, Thomas JP, Wiebe L, Kelly T, Erickson B, Wang H, Evans DB, George B) Oncologist 2014 Mar;19(3):266-74 PMID: 24569947 PMCID: PMC3958454 02/27/2014
  • Staging chest computed tomography and positron emission tomography in patients with pancreatic adenocarcinoma: utility or futility? (Pappas SG, Christians KK, Tolat PP, Mautz AP, Lal A, McElroy L, Gamblin TC, Turaga KK, Tsai S, Erickson B, Ritch P, Evans DB) HPB (Oxford) 2014 Jan;16(1):70-4 PMID: 23496023 PMCID: PMC3892317 03/19/2013
  • Global, multicenter, randomized, phase II trial of gemcitabine and gemcitabine plus AGS-1C4D4 in patients with previously untreated, metastatic pancreatic cancer. (Wolpin BM, O'Reilly EM, Ko YJ, Blaszkowsky LS, Rarick M, Rocha-Lima CM, Ritch P, Chan E, Spratlin J, Macarulla T, McWhirter E, Pezet D, Lichinitser M, Roman L, Hartford A, Morrison K, Jackson L, Vincent M, Reyno L, Hidalgo M) Ann Oncol 2013 Jul;24(7):1792-801 PMID: 23448807 PMCID: PMC3716216 03/02/2013
  • Distal splenorenal and temporary mesocaval shunting at the time of pancreatectomy for cancer: initial experience from the Medical College of Wisconsin. (Christians KK, Riggle K, Keim R, Pappas S, Tsai S, Ritch P, Erickson B, Evans DB) Surgery 2013 Jul;154(1):123-31 PMID: 23305596 01/12/2013
  • Multicenter, randomized phase II trial of bevacizumab plus folinic acid, fluorouracil, gemcitabine (FFG) versus bevacizumab plus folinic acid, fluorouracil, oxaliplatin (FOLFOX4) as first-line therapy for patients with advanced colorectal cancer. (Madajewicz S, Waterhouse DM, Ritch PS, Khan MQ, Higby DJ, Leichman CG, Malik SK, Hentschel P, Gill JF, Zhao L, Nicol SJ) Invest New Drugs 2012 Apr;30(2):772-8 PMID: 21120580 12/02/2010
  • Borderline resectable pancreatic cancer: definitions and the importance of multimodality therapy. (Evans DB, Erickson BA, Ritch P) Ann Surg Oncol 2010 Nov;17(11):2803-5 PMID: 20737218 08/26/2010
  • Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules. (Demetri GD, Chawla SP, von Mehren M, Ritch P, Baker LH, Blay JY, Hande KR, Keohan ML, Samuels BL, Schuetze S, Lebedinsky C, Elsayed YA, Izquierdo MA, G√≥mez J, Park YC, Le Cesne A) J Clin Oncol 2009 Sep 01;27(25):4188-96 PMID: 19652065 08/05/2009
  • Palliative stenting for late malignant gastric outlet obstruction. (Kiely JM, Dua KS, Graewin SJ, Nakeeb A, Erickson BA, Ritch PS, Wilson SD, Pitt HA) J Gastrointest Surg 2007 Jan;11(1):107-13 PMID: 17390196 03/29/2007
  • Improved survival in resected biliary malignancies. (Nakeeb A, Tran KQ, Black MJ, Erickson BA, Ritch PS, Quebbeman EJ, Wilson SD, Demeure MJ, Rilling WS, Dua KS, Pitt HA) Surgery 2002 Oct;132(4):555-63; discission 563-4 PMID: 12407338 10/31/2002
  • Study of either ifosfamide or teniposide compared to a standard chemotherapy for extensive disease small cell lung cancer: an Eastern Cooperative Oncology Group randomized study (E1588). (Ettinger DS, Finkelstein DM, Ritch PS, Lincoln ST, Blum RH, Eastern Cooperative Oncology Group) Lung Cancer 2002 Sep;37(3):311-8 PMID: 12234701 09/18/2002
  • p21WAF1 expression is associated with improved survival after adjuvant chemoradiation for pancreatic cancer. (Ahrendt SA, Brown HM, Komorowski RA, Zhu YR, Wilson SD, Erickson BA, Ritch PS, Pitt HA, Demeure MJ) Surgery 2000 Oct;128(4):520-30 PMID: 11015084 10/03/2000
  • Molecular metastases in stage I pancreatic cancer: improved survival with adjuvant chemoradiation. (Demeure MJ, Doffek KM, Komorowski RA, Redlich PN, Zhu YR, Erickson BA, Ritch PS, Pitt HA, Wilson SD) Surgery 1998 Oct;124(4):663-9 PMID: 9780986 10/22/1998
  • Evaluation of continuous-infusion gallium nitrate and hydroxyurea in combination for the treatment of refractory non-Hodgkin's lymphoma. (Chitambar CR, Zahir SA, Ritch PS, Anderson T) Am J Clin Oncol 1997 Apr;20(2):173-8 PMID: 9124195 04/01/1997
  • An ECOG phase II study of amonafide in unresectable or recurrent carcinoma of the head and neck (PB390). Eastern Cooperative Oncology Group. (Leaf AN, Neuberg D, Schwartz EL, Wadler S, Ritch PS, Dutcher JP, Adams GL) Invest New Drugs 1997;15(2):165-72 PMID: 9220297 01/01/1997
  • Phase I/IB study of polyadenylic-polyuridylic acid in patients with advanced malignancies: clinical and biologic effects. (Witt PL, Zahir S, Ritch PS, McAuliffe TM, Ewel CH, Borden EC) J Interferon Cytokine Res 1996 Aug;16(8):631-5 PMID: 8877734 08/01/1996
  • Hematologic and immunologic evaluation of recombinant human interleukin-6 in patients with advanced malignant disease: evidence for monocyte activation. (Keever-Taylor CA, Witt PL, Truitt RL, Ramanujam S, Borden EC, Ritch PS) J Immunother Emphasis Tumor Immunol 1996 May;19(3):231-43 PMID: 8811498 05/01/1996
  • Phase IA/IB evaluation of mammalian cell-derived glycosylated recombinant human interleukin (SIGOSIX) before and after cytotoxic chemotherapy. (Ritch PS, Keever C, Schiller J, Rivkin S, Witt PL, Grossberg SE, Truitt RL, Burris H, von Hoff DD, Vaickus L) Ann N Y Acad Sci 1995 Jul 21;762:359-60 PMID: 7668536 07/21/1995
  • Randomized placebo-controlled multicenter evaluation of diethyldithiocarbamate for chemoprotection against cisplatin-induced toxicities. (Gandara DR, Nahhas WA, Adelson MD, Lichtman SM, Podczaski ES, Yanovich S, Homesley HD, Braly P, Ritch PS, Weisberg SR) J Clin Oncol 1995 Feb;13(2):490-6 PMID: 7844610 02/01/1995
  • Phase I trial of an oral immunomodulator and interferon inducer in cancer patients. (Witt PL, Ritch PS, Reding D, McAuliffe TL, Westrick L, Grossberg SE, Borden EC) Cancer Res 1993 Nov 01;53(21):5176-80 PMID: 8221654 11/01/1993
  • Imaging of regional spread of breast cancer by internal mammary lymphoscintigraphy, CT, and MRI. (Turoglu HT, Janjan NA, Thorsen MK, Shaffer KA, Ritch PS, Hansen RM, Walker AP, Gai M, Collier BD) Clin Nucl Med 1992 Jun;17(6):482-4 PMID: 1617843 06/01/1992
  • Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia. (Wiernik PH, Banks PL, Case DC Jr, Arlin ZA, Periman PO, Todd MB, Ritch PS, Enck RE, Weitberg AB) Blood 1992 Jan 15;79(2):313-9 PMID: 1730080 01/25/1992
  • Twice-daily tapering dexamethasone treatment during cranial radiation for newly diagnosed brain metastases. (Weissman DE, Janjan NA, Erickson B, Wilson FJ, Greenberg M, Ritch PS, Anderson T, Hansen RM, Chitambar CR, Lawton CA) J Neurooncol 1991 Dec;11(3):235-9 PMID: 1726656 12/01/1991
  • Evaluation of continuous infusion low-dose 5-azacytidine in the treatment of myelodysplastic syndromes. (Chitambar CR, Libnoch JA, Matthaeus WG, Ash RC, Ritch PS, Anderson T) Am J Hematol 1991 Jun;37(2):100-4 PMID: 1712548 06/01/1991
  • Continuous 5-fluorouracil infusion and alpha interferon in advanced cancers: a report of initial treatment results. (Hansen RM, Ritch PS, Libnoch JA, Anderson T) Am J Med Sci 1991 Apr;301(4):246-9 PMID: 2012109 04/01/1991
  • Treatment of hypercalcemia of malignancy with intravenous etidronate. A controlled, multicenter study. The Hypercalcemia Study Group. (Singer FR, Ritch PS, Lad TE, Ringenberg QS, Schiller JH, Recker RR, Ryzen E) Arch Intern Med 1991 Mar;151(3):471-6 PMID: 1900410 03/01/1991
  • Randomized comparison of doxorubicin and vindesine to doxorubicin for patients with metastatic soft-tissue sarcomas. (Borden EC, Amato DA, Edmonson JH, Ritch PS, Shiraki M) Cancer 1990 Sep 01;66(5):862-7 PMID: 2201431 09/01/1990
  • Treatment of cancer-related hypercalcemia. (Ritch PS) Semin Oncol 1990 Apr;17(2 Suppl 5):26-33 PMID: 2185550 04/01/1990
  • Phase II trial of methylglyoxal-bis(guanylhydrazone) (MGBG) in patients with refractory multiple myeloma: an Eastern Cooperative Oncology Group (ECOG) study. (Winter JN, Ritch PS, Rosen ST, Oken MM, Wolter JM, Wiernik PH, O'Connell MJ) Cancer Invest 1990;8(2):143-6 PMID: 2205334 01/01/1990
  • A pilot study of short-course, high-dose cytosine arabinoside, etoposide, and cisplatin in refractory, aggressive-histology, non-Hodgkin's lymphomas. (Schiller JH, Ritch PS, Storer B, Trump DL) Am J Clin Oncol 1989 Dec;12(6):502-6 PMID: 2589231 12/01/1989
  • T-cell non-Hodgkin lymphoma in human immunodeficiency virus-1-infected individuals. (Lust JA, Banks PM, Hooper WC, Paya CV, Kueck BD, Hanson GA, Ritch PS, Woloschak GE) Am J Hematol 1989 Jul;31(3):181-7 PMID: 2500850 07/01/1989
  • Yersinia enterocolitica serotype O:3 sepsis after blood transfusion. (Bufill JA, Ritch PS) N Engl J Med 1989 03 23;320(12):810 PMID: 2922034 03/23/1989
  • A multicenter trial of cytarabine plus idarubicin or daunorubicin as induction therapy for adult nonlymphocytic leukemia. (Wiernik PH, Case DC Jr, Periman PO, Arlin ZA, Weitberg AB, Ritch PS, Todd MB) Semin Oncol 1989 Feb;16(1 Suppl 2):25-9 PMID: 2928807 02/01/1989
  • Pityrosporum folliculitis after bone marrow transplantation. Clinical observations in five patients. (Bufill JA, Lum LG, Caya JG, Chitambar CR, Ritch PS, Anderson T, Ash RC) Ann Intern Med 1988 Apr;108(4):560-3 PMID: 3279893 04/01/1988
  • Cis-dichlorodiammineplatinum II-induced syndrome of inappropriate secretion of antidiuretic hormone. (Ritch PS) Cancer 1988 Feb 01;61(3):448-50 PMID: 2827877 02/01/1988
  • Reversal of autoimmune hemolytic anemia associated with chronic lymphocytic leukemia following high-dose immunoglobulin. (Ritch PS, Anderson T) Cancer 1987 Dec 01;60(11):2637-40 PMID: 3677002 12/01/1987
  • Continuous 5-fluorouracil infusion and pulse methotrexate/leucovorin for colorectal adenocarcinoma. A report of excessive toxicity. (Hansen RM, Quebbeman EJ, Ritch PS, Frick J, Anderson T) Am J Clin Oncol 1987 Jun;10(3):216-8 PMID: 3496002 06/01/1987
  • Ketoconazole in the prevention of candidiasis in patients with cancer. A prospective, randomized, controlled, double-blind study. (Hansen RM, Reinerio N, Sohnle PG, Abrams RA, Ritch PS, Libnoch JA, Anderson T) Arch Intern Med 1987 Apr;147(4):710-2 PMID: 3548626 04/01/1987
  • The antiherpesvirus activity and cytotoxicity of sangivamycin. (O'Brien WJ, Taylor JL, O'Malley TP, Ritch PS) Curr Eye Res 1987 Jan;6(1):255-7 PMID: 3030647 01/01/1987
  • Efficacy of oral administration of etidronate disodium in maintaining normal serum calcium levels in previously hypercalcemic cancer patients. (Ringenberg QS, Ritch PS) Clin Ther 1987;9(3):318-25 PMID: 3111705 01/01/1987
  • Aminoglycoside serum concentration sampling via central venous catheters: a potential source of clinical error. (Franson TR, Ritch PS, Quebbeman EJ) JPEN J Parenter Enteral Nutr 1987 Jan-Feb;11(1):77-9 PMID: 3820521 01/01/1987
  • Sequential methotrexate, 5-fluorouracil, and calcium leucovorin in colorectal carcinoma. (Hansen RM, Ritch PS, Anderson T) Am J Clin Oncol 1986 Aug;9(4):352-4 PMID: 3489407 08/01/1986
  • Clostridial septicemia complicating the course of leukemia. (Caya JG, Farmer SG, Ritch PS, Wollenberg NJ, Tieu TM, Oechler HW, Spivey M) Cancer 1986 May 15;57(10):2045-8 PMID: 3456820 05/15/1986
  • Treatment of intraocular lymphoma with high-dose Ara-C. (Baumann MA, Ritch PS, Hande KR, Williams GA, Topping TM, Anderson T) Cancer 1986 Apr 01;57(7):1273-5 PMID: 2418934 04/01/1986
  • Successful high-dose intravenous cytarabine treatment of parenchymal brain involvement from malignant lymphoma. (Frick JC, Hansen RM, Anderson T, Ritch PS) Arch Intern Med 1986 Apr;146(4):791-2 PMID: 3963961 04/01/1986
  • A randomized study of adjuvant chemotherapy for cancer of the upper aerodigestive tract. (Kun LE, Toohill RJ, Holoye PY, Duncavage JA, Byhardt RW, Ritch PS, Grossman TW, Hoffmann RG, Cox JD, Malin T) Int J Radiat Oncol Biol Phys 1986 Feb;12(2):173-8 PMID: 2419292 02/01/1986
  • Randomized study of adjuvant chemotherapy for head and neck cancer. (Holoye PY, Grossman TW, Toohill RJ, Kun LE, Byhardt RW, Duncavage JA, Teplin RW, Ritch PS, Hoffman RG, Malin TC) Otolaryngol Head Neck Surg 1985 Dec;93(6):712-7 PMID: 2418400 12/01/1985
  • Skin rash following therapy with mitomycin C. (Ritch PS, Louie AC) Cancer 1984 Jul 01;54(1):32-3 PMID: 6232996 07/01/1984
  • Successful treatment of meningeal leukemia using systemic high-dose cytosine arabinoside. (Frick J, Ritch PS, Hansen RM, Anderson T) J Clin Oncol 1984 May;2(5):365-8 PMID: 6726293 05/01/1984
  • Blood-handling precautions and the human T-leukemia virus. (Franson TR, Abrams RA, Ritch PS) Ann Intern Med 1984 May;100(5):765 PMID: 6324626 05/01/1984
  • Chronic granulocytic leukemia following radiation therapy for Hodgkin's disease. (Ritch PS, Anderson T, Hanson GA, Pisciotta AV) Cancer 1983 Aug 01;52(3):462-4 PMID: 6574804 08/01/1983
  • A practical graphical method for estimating the fraction of cells in S in DNA histograms from clinical tumor samples containing aneuploid cell populations. (Ritch PS, Shackney SE, Schuette WH, Talbot TL, Smith CA) Cytometry 1983 Jul;4(1):66-74 PMID: 6617396 07/01/1983
  • Prophylaxis of ifosfamide toxicity with oral acetylcysteine. (Holoye PY, Duelge J, Hansen RM, Ritch PS, Anderson T) Semin Oncol 1983 Mar;10(1 Suppl 1):66-71 PMID: 6836329 03/01/1983
  • Metastatic renal cell carcinoma presenting as shoulder arthritis. (Ritch PS, Hansen RM, Collier BD) Cancer 1983 Mar 01;51(5):968-72 PMID: 6821862 03/01/1983
  • Ocular toxicity from high-dose cytosine arabinoside. (Ritch PS, Hansen RM, Heuer DK) Cancer 1983 Feb 01;51(3):430-2 PMID: 6571799 02/01/1983
  • Use and safety of high-dose ifosfamide. (Holoye PY, Anderson T, Duelge J, Hansen RM, Ritch PS) Semin Oncol 1982 Dec;9(4 Suppl 1):78-86 PMID: 6298946 12/01/1982
  • Schedule optimization of hydroxyurea and 1-beta-D-arabinofuranosylcytosine in sarcoma 180 in vitro. (Shackney SE, Ford SS, Occhipinti SJ, Ritch PS, Riccardi R, Erickson BW Jr) Cancer Res 1982 Nov;42(11):4339-47 PMID: 7127279 11/01/1982
  • Transient polyradiculoneuropathy following a febrile transfusion reaction. (Ritch PS, Hansen RM, McQuillen MP) Arch Neurol 1982 Sep;39(9):597-8 PMID: 7115155 09/01/1982
  • Pyrrolopyrimidine lethality in relation to ribonucleic acid synthesis in sarcoma 180 cells in vitro. (Ritch PS, Helmsworth M) Biochem Pharmacol 1982 Aug 15;31(16):2686-8 PMID: 6982713 08/15/1982
  • Increased relative effectiveness of doxorubicin against slowly proliferating sarcoma 180 cells after prolonged drug exposure. (Ritch PS, Occhipinti SJ, Skramstad KS, Shackney SE) Cancer Treat Rep 1982 May;66(5):1159-68 PMID: 7083218 05/01/1982
  • Preferential incorporation of sangivamycin into ribonucleic acid in Sarcoma 180 cells in vitro. (Ritch PS, Glazer RI) Biochem Pharmacol 1982 Jan 15;31(2):259-61 PMID: 7059368 01/15/1982
  • Schedule-dependent synergism of combinations of hydroxyurea with adriamycin and 1-beta-D-arabinofuranosylcytosine with adriamycin. (Ritch PS, Occhipinti SJ, Cunningham RE, Shackney SE) Cancer Res 1981 Oct;41(10):3881-4 PMID: 7284997 10/01/1981
  • Kinetic effects of sangivamycin in sarcoma 180 in vitro. (Ritch PS, Glazer RI, Cunningham RE, Shackney SE) Cancer Res 1981 May;41(5):1784-8 PMID: 7214345 05/01/1981
  • Disseminated BCG disease associated with immunotherapy by scarification in acute leukemia. (Ritch PS, McCredie KB, Gutterman JU, Hersh EM) Cancer 1978 Jul;42(1):167-70 PMID: 276413 07/01/1978
  • Last update: 10/24/2012
    jenkins-FCD Prod-130 96200611f8481f0aa4f84230b11dd74d063847a3